Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 2546 • ACR Convergence 2023
Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up
CLARISSA PIMENTEL, ANA CRISTINA MEDEIROS-RIBEIRO, ANDREA SHIMABUCO, PERCIVAL SAMPAIO-BARROS, JULIO CESAR MORAES, CLAUDIA SCHAINBERG, CELIO GONÇALVES, ELAINE LEON, LEONARD KUPPA, Sandra Pasoto, NADIA AIKAWA, CLOVIS SILVA, Eloisa Bonfa and CARLA SAAD, University of São Paulo, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) therapies were one of the major advances in the treatment of Ankylosing Spondylitis (AS) patients. For infliximab, anti-drug antibodies…
Abstract Number: 0361 • ACR Convergence 2023
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
Leah Medrano and Alice Hoftman, David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…
Abstract Number: 0838 • ACR Convergence 2023
Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections
Russell Ross¹, Vibeke Strand², Roel Querubin³, John Goldman⁴, Richard Leff⁵, Alexis Melson¹, Pei-Ling Roerig⁶ and Alan Smith⁷, ¹Sorrento Therapeutics, Atlanta, GA, ²Stanford University, Portola Valley, CA, ³Marietta Rheumatology Associates, Marietta, GA, ⁴Northside Hospital, Atlanta, GA, ⁵Kezar Life Sciences, Chadds Ford, PA, ⁶4P Therapeutics, Orlando, FL, ⁷4P Therapeutics, Atlanta, GA
Background/Purpose: The lymphatic system serves as a conduit for transporting immune cells and inflammatory molecules present in arthritic joints to lymph nodes (LN), playing a…
Abstract Number: 1678 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², Jean liew³, K Wysham⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³Boston University, Boston, MA, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: In the ORAL Surveillance trial, cancer risk was higher among patients with rheumatoid arthritis (RA) on tofacitinib, a Janus kinase inhibitor (JAKi), compared to…
Abstract Number: 2550 • ACR Convergence 2023
The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis
Zijing Yang¹, Maryam Adas¹, Bechman Katie¹, Deepak Nagra¹, Ali Soykan Uguzlar¹, Mark Russell¹, Nicky Wilson², Sophia Steer¹, Sam Norton¹ and James Galloway¹, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Anterior uveitis (AU) is one of the commonly observed extraspinal manifestations in Axial spondyloarthritis (AxSpA). Data on the protective effects of targeted immunomodulatory therapies…
Abstract Number: 0370 • ACR Convergence 2023
Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis
Melissa Oliver¹, Kelly Mosesso², Pamela F. Weiss³, Robert Colbert⁴, Matthew Stoll⁵ and Hemalatha Srinivasalu⁶, ¹Indiana University, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴NIH/NIAMS, Bethesda, MD, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Children's National Hospital, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…
Abstract Number: 0970 • ACR Convergence 2023
Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change
Diane Lacaille¹, J. Antonio Avina-Zubieta², Yufei Zheng², Na Lu² and Hui Xie³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Simon Fraser University, Richmond, BC, Canada
Background/Purpose: British Columbia's health policy mandated that all new anti-TNF initiations after June 2017 use biosimilars when available, providing the context for a natural experiment.…
Abstract Number: 1729 • ACR Convergence 2023
An Antibody-drug Conjugate of Anti-TNFα Antibody and a Novel Glucocorticoid Molecule Exerts Synergistic Anti-inflammatory Effects for Treatment of Autoimmune Diseases
Yuhao Qin¹, Wenming Ren², Liangqin Tong³, lu su³ and cheng liao³, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China, ²Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pudong New District, China, ³Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
Background/Purpose: Tumor necrosis factor α (TNFα) is a pivotal pro-inflammatory cytokine. And TNF inhibitors are the most successful anti-rheumatic drugs for the treatment of autoimmune…
Abstract Number: 0428 • ACR Convergence 2023
Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk², Orit Schieir³, Marie-France Valois⁴, Susan Bartlett⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Edward Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Diane Tin¹², Glen Hazlewood¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹³, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York, NY, ³McGill University, Montréal, QC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Manitoba, Manitoba, MB, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Centre of Arthritis Excellence, Newmarket, ON, Canada, ¹³CATCH, Toronto, ON, Canada
Background/Purpose: Recent Canadian treatment recommendations suggest offering to taper of biologic or targeted synthetic therapy to patients with rheumatoid arthritis (RA) after they achieve sustained…
Abstract Number: 0973 • ACR Convergence 2023
Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Yeo-Jin Song¹, Jungyong Han², Hye Won Kim³, Eunwoo Nam³, Sang Won Lee⁴, Shin-Seok Lee⁵, Hye-Soon Lee⁶, Sung-Hoon Park⁷, Yeon-Ah Lee⁸, Sung Hae Chang⁹, Min-Chan Park¹⁰, Hyoun-Ah Kim¹¹, Hyun-Sook Kim¹², Bo Young Yoon¹³, Yong-Gil Kim¹⁴, Hae-Rim Kim¹⁵, Jae Hoon Kim¹⁶, Jisoo Lee¹⁷, Jeongim Choi¹⁸, Wan-Sik Uhm¹⁹ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ⁴Hanyang University, Seoul, South Korea, ⁵Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁶Hanyang University, Guri, South Korea, ⁷Daegu Catholic University School of Medicine, Daegu, South Korea, ⁸Kyung Hee University Hospital, Seoul, South Korea, ⁹Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ¹⁰Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ¹¹Ajou University School of Medicine, Suwon, South Korea, ¹²Soonchunhyang University Seoul Hospital, Seoul, South Korea, ¹³Inje University Ilsan Paik Hospital, Goyang, South Korea, ¹⁴Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ¹⁵Rheumatology, Konkuk University Medical Center, Seoul, South Korea, ¹⁶Korea University Medical Center, Seoul, South Korea, ¹⁷Ewha Womans Univ College of Medicine, Seoul, South Korea, ¹⁸Busan Saint Mary's Hospital, Busan, South Korea, ¹⁹Uhm's Rheumatism Clinic, Seoul, South Korea
Background/Purpose: Although clinical trials have shown similar effectiveness between Janus kinase inhibitors (JAKi) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), the choice between these two options…
Abstract Number: 1731 • ACR Convergence 2023
A Competitive Inhibitor of MOART Showed Potent Therapeutic Effects in a Mouse Model of Collagen-induced Arthritis
Sujin Park¹, DongWoo Kang², Haein An¹, Eunji Hong¹, Kwiyeom Yoon², MinWoo Kim², Hwajung Kim² and Seong Jin Kim², ¹GILO Institute, GILO Foundation, Seoul, South Korea, ²Medpacto Inc., Seoul, South Korea
Background/Purpose: Despite tumor necrosis factor (TNF) inhibitors and Jak kinase inhibitors (JKI) have shown a significant advance in the treatment of rheumatoid arthritis (RA) however,…
Abstract Number: 0441 • ACR Convergence 2023
Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Dimitrios Pappas¹, Jacqueline O’Brien¹, Lin Guo¹, Ying Shan¹, Joshua Baker², Gregory Kricorian³, Scott Stryker⁴ and David Collier³, ¹CorEvitas, LLC, Waltham, MA, ²University of Pennsylvania, Philadelphia, PA, ³Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA
Background/Purpose: Ongoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as…
Abstract Number: 0978 • ACR Convergence 2023
Identifying Important Clinical Features for Predicting Remission in Patients with Rheumatoid Arthritis Treated with Biologics Using Machine Learning Model
Ahmad Alsaber¹, Adeeba AlHerz², Balqees Alawadhi³, Parul Setiya⁴, KHULOUD MOHAMMED⁵, Adel Al-Awadhi⁶, Waleed Al-Kandari⁷, Eman Hasan⁸, Khaled Mokaddem⁹, Aqeel Ghanem¹⁰, Youssef Bartella¹¹, Mohammed Hussain⁸, Naser Alhadhood¹², Yaser Ali¹³, Ebrahim Nahar¹³, Ali Aldei⁸, Ahmad Alenizi¹⁴, Sawsan Hayat¹⁵, Fatemah Abutiban¹⁶ and Fatemah Abutiban¹¹, ¹American University of Kuwait, Kuwait City, Kuwait, ²Al-Amiri Hospital, Al Asimah Governate, Kuwait, ³The Public Authority for Applied Education and Training, Kuwait City, Kuwait, ⁴GBPUAT, Department of Agrometerology, Pantnagar, India, ⁵Farwaniya Hospital, Kuwait, Kuwait, ⁶Kuwait University, Kuwait City, Kuwait, ⁷Farwaniya Hospital, Division of Rheumatology, Ministry of Health, Kuwait, Kuwait, ⁸Amiri Hospital, Division of Rheumatology, Kuwait City, Kuwait, ⁹Al-Amiri Hospital, Rheumatoid, Al Kuwayt, Kuwait City, Kuwait, ¹⁰Mubarak Al-Kabeer Hospital, Division of Rheumatology, Kuwait City, Kuwait, ¹¹Farwaniya Hospital, Department of Rheumatology, Kuwait, Kuwait, ¹²Farwaniya Hospital, Kuwait City, Kuwait, ¹³Mubarak Al-Kabeer Hospital, Department of Rheumatology, Jabriya, Kuwait, ¹⁴Jahra Hospital, Al Jahra, NY, Kuwait, ¹⁵Ministry of Health - Kuwait, Jabriya, Kuwait, ¹⁶Jahra Hospital, Department of Medicine, Al Jahra, Kuwait
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) offer promising results for rheumatoid arthritis (RA) patients in general, but a substantial percentage of patients do not respond…
Abstract Number: 1779 • ACR Convergence 2023
A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
Smadar Gertel¹, Victoria Furer¹, Ari Polachek¹ and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated condition that results in systemic musculoskeletal (MSK) inflammation, including peripheral synovitis, enthesitis and axial involvement. Glucocorticoids (GCs)…
Abstract Number: 0443 • ACR Convergence 2023
The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis
Anna Fishbein¹, Mai Anh Nguyen², Ohn Chow³, Tiago Matos⁴, Caroline Dreis⁵, Hong Zhang³, Marion Poirel⁶, Johann Gassenhuber⁵, Michael Dufault³, Wagner Frank-Dietrich⁷, Laurent Perrin⁸, Markus Rehberg⁵, Markus Kohlmann⁵ and Nassr Nassr⁵, ¹Sanofi, Bridgewater, NJ, ²Sanofi, Berlin, Germany, ³Sanofi, Cambridge, MA, ⁴Sanofi, Amsterdam, Netherlands, ⁵Sanofi, Frankfurt, Germany, ⁶IT&M Stats, Neuilly-sur-Seine, France, ⁷Charité Research Organisation, Berlin, Germany, ⁸Sanofi, Montpellier, France
Background/Purpose: TNFα inhibition is a cornerstone of therapy for rheumatologic disease, yet there is no orally administered TNFα inhibitor available. A novel oral TNFα inhibitor…

« Previous Page
1
…
4
5
6
7
8
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].